Literature DB >> 27315825

Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia-Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears.

Eyad Alhourani1, Rouben Aroutiounian2, Tigran Harutyunyan2, Anita Glaser1, Cordula Schlie1, Beate Pohle1, Thomas Liehr1.   

Abstract

Banding cytogenetics is still the gold standard in many fields of leukemia diagnostics. However, in chronic lymphocytic leukemia (CLL), GTG-banding results are hampered by a low mitotic rate of the corresponding malignant lymphatic cells. Thus, interphase fluorescence in situ hybridization (iFISH) for the detection of specific cytogenetic aberrations is done nowadays as a supplement to or even instead of banding cytogenetics in many diagnostic laboratories. These iFISH studies can be performed on native blood or bone marrow smears or in nuclei after cultivation and stimulation by a suitable mitogen. As there are only few comparative studies with partially conflicting results for the detection rates of aberrations in cultivated and native cells, this question was studied in 38 CLL cases with known aberrations in 11q22.2, 11q22.3, 12, 13q14.3, 14q32.33, 17p13.1, or 18q21.32. The obtained results implicate that iFISH directly applied on smears is in general less efficient for the detection of CLL-specific genetic abnormalities than for cultivated cells. This also shows that applied cell culture conditions are well suited for malignant CLL cells. Thus, to detect malignant aberrant cells in CLL, cell cultivation and cytogenetic workup should be performed and the obtained material should be subjected to banding cytogenetics and iFISH.
© 2016 The Histochemical Society.

Entities:  

Keywords:  TPA stimulation and cell cultivation; blood or bone marrow smears; chronic lymphocytic leukemia (CLL); interphase fluorescence in situ hybridization (iFISH)

Mesh:

Year:  2016        PMID: 27315825      PMCID: PMC4971778          DOI: 10.1369/0022155416655086

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  21 in total

1.  Detection of chromosomal abnormalities in chronic lymphocytic leukemia increased by interphase fluorescence in situ hybridization in tetradecanoylphorbol acetate-stimulated peripheral blood cells.

Authors:  Jana Sánchez; Anna Aventín
Journal:  Cancer Genet Cytogenet       Date:  2007-05

2.  Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease.

Authors:  Christian Philipp Pallasch; Alexandra Schulz; Nadine Kutsch; Janine Schwamb; Susanne Hagist; Hamid Kashkar; Alfred Ultsch; Claudia Wickenhauser; Michael Hallek; Clemens-Martin Wendtner
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

3.  Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.

Authors:  M Bentz; G Cabot; M Moos; M R Speicher; A Ganser; P Lichter; H Döhner
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

4.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

5.  Optimized mitogen stimulation induces proliferation of neoplastic B cells in chronic lymphocytic leukemia: significance for cytogenetic analysis.The Tampere Chronic Lympocytic Leukemia group.

Authors:  M L Larramendy; S M Siitonen; Y Zhu; M Hurme; L Vilpo; J A Vilpo; S Knuutila
Journal:  Cytogenet Cell Genet       Date:  1998

6.  Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA.

Authors:  M Carlsson; T H Tötterman; P Matsson; K Nilsson
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

Review 7.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

8.  De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Authors:  Constantine S Tam; Tait D Shanafelt; William G Wierda; Lynne V Abruzzo; Daniel L Van Dyke; Susan O'Brien; Alessandra Ferrajoli; Susan A Lerner; Alice Lynn; Neil E Kay; Michael J Keating
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

9.  Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH).

Authors:  Eyad Alhourani; Martina Rincic; Moneeb Ak Othman; Beate Pohle; Cordula Schlie; Anita Glaser; Thomas Liehr
Journal:  Mol Cytogenet       Date:  2014-11-19       Impact factor: 2.009

10.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.